



FINANCIAL TEAR SHEET

Corporate Profile

Apricus is committed to developing sexual health therapies in areas of high unmet needs. We have disciplined leadership focused on execution and are driving near-term shareholder value through regulatory approval, commercialization and partnering initiatives.

Stock Performance

APRI (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$0.26
Change (%)	0.00 (0.00%)
Volume	350,371
52 Week High	\$3.34
52 Week Low	\$0.25
Market Cap	\$6,036,078
Rolling EPS	-1.07
PE Ratio	0
Shares Outstanding	23,441,080

Data as of 04/26/18 4:00 p.m. ET



Recent Headlines

- 04/16/18 [Apricus Biosciences Announces Outcome of Vitaros™ End-of-Review Meeting with FDA](#)
- 04/04/18 [Apricus Biosciences Announces Closing of \\$3.55 Million Public Offering](#)
- 03/28/18 [Apricus Biosciences Announces Pricing of \\$3.55 Million Public Offering](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
04/16/18	8-K
04/09/18	SC 13G
04/06/18	EFFECT
04/06/18	DEF 14A

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)

© Apricus Biosciences, Inc.